Reuters
14 Jun 2026, 19:47 UTC · 9h ago
Lundbeck drug candidate shows promise in Cushing's disease trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
14 Jun 2026, 19:47 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
H. Lundbeck's investigational drug asedebart showed encouraging results and tolerability in a mid-stage study for Cushing's disease. — Positive mid-stage clinical data increases the probability of drug approval and future revenue streams for the company.
+0.40Which stocks this story touches
The company reported encouraging tolerability and results for its investigational drug asedebart.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
1d ago
